Kura Oncology KURA KOMZIFTI — Royalty Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The source filing: Kura Oncology’s 10-K, filed March 5, 2026.
- Filed
- Mar 5, 2026, 7:31 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-092567
Collectively, our license agreements provide for specified development, regulatory and sales-based milestone payments up to a total of $80.2 million payable upon occurrence of each stated event, of which $0.5 million relates to the initiation of certain development activities, $28.9 million relates to the achievement of specified regulatory approvals for the first indication and up to $50.8 million relates to the achievement of specified levels of product sales. Additional payments will be due for each subsequent indication if specified regulatory approvals are achieved. Furthermore, if all the programs are successfully commercialized, we will be required to pay sublicense fees and tiered royalties on annual net product sales ranging from the low single digits to the low teens, depending on the volume of sales and the respective agreement. For the year ended December 31, 2025, we incurred sublicense fees of $5.0 million. As of December 31, 2025, we have paid milestone payments totaling $1.4 million and incurred sublicense fees totaling $9.8 million. For the year ended December 31, 2025, we incurred royalties of approximately $0.1 million related to the product sales of KOMZIFTI.
Item 16. Form 10-K Summary.
FAQ
- What is Kura Oncology's KOMZIFTI — royalty expense?
- Kura Oncology (KURA) reported KOMZIFTI — royalty expense of $25K in Q4 2025.
- What does KOMZIFTI — royalty expense mean?
- This metric represents the total costs incurred by the company for royalty payments associated with the commercialization or development of the specified product segment. These expenses typically arise from licensing agreements or intellectual property rights held by third parties that are triggered by product sales or development milestones. Monitoring this figure is essential for assessing the impact of external technology dependencies on the overall gross margin and profitability of the product line.
Ask your AI about Kura Oncology's komzifti — royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
